Nebenwirkungen · Trelegy Ellipta
Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed · Abschnitt 4.8 · PDF-Seite 8–9
HOS-138237 · Präparat HOS-098164
8 1% of patients receiving Trelegy Ellipta and <1% of patients receiving budesonide/formoterol up to 24 weeks. One fatal case of pneumonia was reported in a patient who received Trelegy Ellipta. In the subset of 430 patients treated for up to 52 weeks, the incidence of pneumonia events reported in both Trelegy Ellipta and budesonide/formoterol arms was equal at 2%. The incidence of pneumonia with Trelegy Ellipta is comparable with that observed in the fluticasone furoate/vilanterol (FF/VI) 100/25 arm of FF/VI clinical studies in COPD.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T12:00:00Z · SHA-256 da8a456ad1e55d2f32bd6c089e4b8c46019bb784e9ff1f604d031e5d487eea91 · Passage 3c6964ca9c8da553237e025246e64600f2ea2317ad3d6b16dbcc114fcd831b40 · Zeichen 4129–4670 im Abschnitt